BACKGROUND: The disruption of the blood–brain barrier (BBB) is a central pathogenic event in many central nervous system disorders. However, the mechanisms regulating BBB function remain incompletely ...
In ALIGN study, Vanrafia (atrasentan) showed positive difference in eGFR change from baseline vs. placebo at Week 136, 4 weeks after study treatment ended1Results favored Vanrafia across multiple ...
In ALIGN study, Vanrafia (atrasentan) showed positive difference in eGFR change from baseline vs. placebo at Week 136, 4 weeks after study treatment ended1Results favored Vanrafia across multiple ...
Whether you're taking a family vacation or a romantic cruise, a flight disruption can throw your plans out of whack. And so far, there've been quite a few this year: Between Jan. 23 and Jan. 26, more ...
(PRESS RELEASE) BASEL, 13-Feb-2026 — / EuropaWire / — Novartis has announced final Phase III results from the ALIGN study evaluating Vanrafia (atrasentan) in adults with IgA nephropathy (IgAN), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results